Tamtam Try Tamtam free
Danaher Corporation logo

Danaher Corporation account plan

Science technology health innovation

At a glance

Danaher is a life sciences and diagnostics group of more than 15 operating companies, with $24,568 million of 2025 sales and about 60,000 associates.

Danaher is a global life sciences and diagnostics group made up of more than 15 operating companies, including Cytiva, Pall, Beckman Coulter, Cepheid, Leica, SCIEX, IDT, Abcam and, since June 2026, Masimo. It sells mostly on a recurring basis and mostly direct, to pharma and biopharma companies, CDMOs, research institutions, hospitals and laboratories, with facilities in approximately 50 countries. In 2025 sales were $24,568 million (core +2.0%), of which recurring revenue was $20,127 million, and net earnings from continuing operations were approximately $3.6 billion ($5.03 per diluted share). Approximately 59% of 2025 sales came from outside the United States, and the group had approximately 60,000 associates at December 31, 2025. It runs on the Danaher Business System (DBS) of continuous improvement.

Business units

Strategic priorities

Danaher Business System
DBS, organised in Growth, Lean, Leadership and Fundamentals pillars, is the first of three strategic priorities, alongside portfolio building through capital allocation and talent; the new CEO aims to leverage it more effectively for more consistent growth.
M&A-led portfolio building
Masimo was acquired on June 10, 2026 for approximately $9.8 billion net of cash, and Leica Biosystems agreed to buy StatLab (approximately $250 million 2025 revenue), expected to close by end-2026; management says its bias to capital deployment is M&A in any of the three segments.
Bioprocessing capex cycle
Management sees a multi-year capex cycle in bioprocessing equipment from brownfield expansion and reshoring, with equipment orders up more than 30% in Q1 2026 and long-term high-single-digit growth expected for bioprocessing.
AI and autonomous science
Danaher treats AI as a growth accelerator for pharma and biotech, driving near-term demand for automation, instruments and reagents; Beckman Coulter Life Sciences partnered with Automata on AI-ready lab automation.
Masimo integration
Targets of $125 million of cost synergies by year 5, about $50 million of revenue synergies and high-single-digit ROIC by the fifth year.
2026 guidance
Full-year core growth of 3% to 4% and adjusted EPS raised to $8.45 to $8.60, with a mid-single-digit core exit rate in Q4.

Latest results

In Q2 2026 (quarter ended June 26, 2026) sales were $6,265 million, up 5.5% reported and 3.0% core, or 4.5% core excluding respiratory testing. Net earnings were $870 million ($1.23 per diluted share) versus $555 million a year earlier, when a $432 million impairment was booked; adjusted EPS was $1.94. High-growth markets grew 15% and were approximately 31% of sales, while developed-market core sales fell slightly. Masimo-related charges cut Q2 operating margin by 175 basis points. For Q3 the company guided core revenue growth of about 2% to 3%, and full-year 2026 adjusted EPS of $8.45 to $8.60.

Investments and deals

Masimo acquisition
Closed June 10, 2026 for approximately $9.8 billion net of cash ($180.00 per share); Masimo had approximately $1.5 billion of 2025 revenue and sits in Diagnostics, financed with cash, long-term debt and commercial paper.
StatLab acquisition
Leica Biosystems agreed to acquire StatLab, a histology consumables maker with approximately $250 million of 2025 revenue and more than 85% recurring revenue, expected to close by end-2026.
Capital expenditure
Capex was approximately $1.2 billion in 2025 for manufacturing capacity, leased instruments, buildings, new products and IT; Pall has a new plant in startup in Singapore.
Share repurchases
$3,088 million of buybacks in 2025 and $894 million in the first half of 2026.

Challenges and risks

China volume-based procurement
China (approximately 11% of sales) cut Diagnostics prices, with a policy headwind of $75 million to $100 million expected in 2026.
Respiratory testing decline
Cepheid respiratory revenue fell approximately 25% in Q1 2026 on a light season; full-year respiratory revenue is expected at about 1.6 billion.
Bioprocessing shipment timing
Large chromatography resin shipments moved out of 2026 at customer request, a shift of a little bit north of $100 million into 2027.
Research funding and policy
Lower funding at emerging biotech, academic and government customers weighed on Life Sciences; academic and government demand remains muted overall.
Debt and tariffs
Total debt rose to approximately $18.4 billion at end-2025 before the Masimo financing; tariff outcomes remain uncertain after the IEEPA ruling, and the Middle East conflict raised logistics costs.

What leadership says

“accelerate innovation, enhance our business capabilities, and more effectively leverage the Danaher Business System”

Julie Sawyer Montgomery, President and CEO (from October 1, 2026) · Press release on her appointment, August 3, 2026

“We are at a uniquely opportune moment for Danaher, with untapped potential to accelerate growth across the enterprise.”

Steven Rales, Chairman · Press release on the CEO appointment, August 3, 2026

“we're in the early innings here of a multi-year capex cycle”

Rainer Blair, President and CEO (then) · Q2 2026 earnings call, July 21, 2026

“we think AI is going to be a growth accelerator for the pharma and biotech industry”

Rainer Blair, President and CEO (then) · Q1 2026 earnings call, April 21, 2026

Where a supplier can help

Masimo and StatLab integration
Integrating Masimo against $125 million of cost synergies and closing StatLab create work for integration, IT, procurement and commercial-enablement suppliers.
Bioprocessing capacity build-out
The multi-year bioprocessing capex cycle and new plants such as Pall's in Singapore point to engineering, automation and construction partners.
AI and lab automation
The AI and autonomous-science priority opens doors for data, software and automation vendors working with Beckman and the Life Sciences businesses.
Commercial capability under a new CEO
Julie Sawyer Montgomery's agenda to enhance business capabilities and leverage DBS more effectively suits sales-enablement, operations and process-improvement providers.
Supply chain and logistics
Tariff uncertainty and higher Middle East logistics costs suggest sourcing and logistics optimisation offers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Danaher Corporation?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Danaher Corporation

What does Danaher do?

Danaher makes life sciences tools, bioprocessing products and diagnostics through more than 15 operating companies such as Cytiva, Pall, Beckman Coulter, Cepheid and Masimo, organised in Biotechnology, Life Sciences and Diagnostics.

What is Danaher's revenue?

2025 sales were $24,568 million, with net earnings from continuing operations of approximately $3.6 billion; Q2 2026 sales were $6,265 million.

How many employees does Danaher have?

Approximately 60,000 associates at December 31, 2025.

Who is Danaher's CEO?

Julie Sawyer Montgomery became President and CEO on October 1, 2026, succeeding Rainer Blair; she previously led the Diagnostics platform.

What is Danaher's strategy?

It rests on the Danaher Business System, portfolio building through acquisitions such as Masimo, and talent, with AI-driven lab automation and the bioprocessing capex cycle as growth themes.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)